CRBG
Corebridge Financial, Inc.
CRBG has the edge over MS overall, supported by stronger valuation and stronger fundamentals.
MS
Morgan Stanley
MS's outlook is improving, though it still trails on the overall score.
CRBG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CRBG's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CRBG.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CRBG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.7x | $35.97 | — |
| Cheap | 7.4x | $33.58 | -6.6% |
| Current | 8x | $35.97 | — |
| Fair | 9.6x | $43.16 | +20% |
| Expensive | 29x | $130 | +262% |
Historical ranges are pointers, not guarantees.
CRBG has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CRBG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CRBG's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over CRBG on the outlook, with more favorable revenue expectations.
CRBG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.39 | +19% |
| Q3 2026 | $4.51 | +178% |
| Q2 2026 | $1.56 | +$2.23 |
| Q1 2026 | $0.40 | -64% |
| Q4 2025 | -$0.68 | -118% |
| Q3 2025 | $1.62 | +$3.69 |
| Q2 2025 | -$0.67 | -121% |
| Q1 2025 | $1.12 | -71% |
| Q4 2024 | $3.72 | +118% |
CRBG earned $4.51 per share over the past year, up 178% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CRBG on earnings, with more consistent year-over-year improvement.
CRBG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.2B | +14% |
| Q2 2026 | $3.9B | +43% |
| Q1 2026 | $4B | +10% |
| Q4 2025 | $6.8B | +2.2% |
| Q3 2025 | $5.4B | +107% |
| Q2 2025 | $2.7B | -26% |
| Q1 2025 | $3.6B | -38% |
| Q4 2024 | $6.6B | +97% |
CRBG's revenue has grown year over year for five quarters in a row: $6.2B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 38% | +39 points |
| Q2 2026 | 1.3% | +24 points |
| Q1 2026 | 2.5% | +27 points |
| Q4 2025 | 14% | -30 points |
| Q3 2025 | -0.8% | +60 points |
| Q2 2025 | -22% | -35 points |
| Q1 2025 | -24% | -41 points |
| Q4 2024 | 44% | +97 points |
CRBG has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CRBG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
CRBG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $605M | +2421% |
| Q2 2026 | -$44M | +$215M |
| Q1 2026 | -$9M | -102% |
| Q4 2025 | $1.9B | +27% |
| Q3 2025 | $24M | -71% |
| Q2 2025 | -$259M | -$250M |
| Q1 2025 | $375M | -37% |
| Q4 2024 | $1.5B | +93% |
CRBG has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CRBG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -7M shares |
| 1 year | -17% | -93.4M shares |
| 3 years | -30% | -194M shares |
CRBG has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $185M |
| Q2 2026 | $300M |
| Q1 2026 | $1.3B |
| Q4 2025 | $1.1B |
| Q3 2025 | $380M |
| Q2 2025 | $311M |
| Q1 2025 | $321M |
| Q4 2024 | $398M |
CRBG spent $2.8B buying back its own shares over the past year, up 101% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
CRBG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | 360.7x | High |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.3x | Net Cash |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 1.9x | Healthy |
CRBG has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CRBG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.8 | Neutral |
| Stochastic | 72.5 | Neutral |
CRBG's weekly RSI is 66 (neutral) and its Stochastic is 73 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CRBG PE vs Financial Services Sector
| Metric | CRBG | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 13x | 39% below |
| PE % | 29 | 57 | 28 pts below |
CRBG has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CRBG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.6 | 4.1% above |
| 20 week MA | $33.4 | 7.7% above |
| 50 week MA | $30.2 | 19% above |
| 100 week MA | $31.1 | 16% above |
| 200 week MA | $27.3 | 32% above |
CRBG has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CRBG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $20.7 | $20.3 | -2.2% |
| 2023 | $20.3 | $21.7 | +6.9% |
| 2024 | $21.7 | $30.0 | +39% |
| 2025 | $30.0 | $30.6 | +1.9% |
| 2026 YTD | $30.6 | $36.0 | +18% |
CRBG has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.